4.8 Article

Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer

期刊

CELL REPORTS
卷 15, 期 3, 页码 599-610

出版社

CELL PRESS
DOI: 10.1016/j.celrep.2016.03.038

关键词

-

资金

  1. NIH [CA134514, CA130908, CA193239, GM63904, P30 DK84567]
  2. DOD [W81XWH-09-1-622, W81XWH-14-1-0486]
  3. Movember Foundation-Prostate Cancer Foundation Challenge Award [2015CHAL518]
  4. Mayo Clinic Center for Individualized Medicine Pilot Award
  5. Mayo Clinic Center for Biomedical Discovery Platform Grant
  6. T.J. Martell Foundation
  7. Program for Changjiang Scholars [IRT1111]
  8. National Basic Research Program of China [2012CB518300]
  9. National Natural Science Foundation of China [81430058, 81472397]
  10. Shanghai Municipal Health and Family Planning Commission Outstanding Young Investigator [XYQ2013077]
  11. Shanghai Municipal Education Commission

向作者/读者索取更多资源

The androgen receptor (AR) is required for castration-resistant prostate cancer (CRPC) progression, but the function and disease relevance of AR-bound enhancers remain unclear. Here, we identify a group of AR-regulated enhancer RNAs (e.g., PSA eRNA) that are upregulated in CRPC cells, patient-derived xenografts (PDXs), and patient tissues. PSA eRNA binds to CYCLIN T1, activates P-TEFb, and promotes cis and trans target gene transcription by increasing serine-2 phosphorylation of RNA polymerase II (Pol II-Ser2p). We define an HIV-1 TAR RNA-like (TAR-L) motif in PSA eRNA that is required for CYCLIN T1 binding. Using TALEN-mediated gene editing we further demonstrate that this motif is essential for increased Pol II-Ser2p occupancy levels and CRPC cell growth. We have uncovered a P-TEFb activation mechanism and reveal altered eRNA expression that is related to abnormal AR function and may potentially be a therapeutic target in CRPC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据